Inogen, Inc. (INGN), Monday announced that the company has received U.S. Food and Drug Administration 510(k) clearance for the SIMEOX 200 Airway Clearance Device, designed to help patients with chronic lung diseases associated with mucus hypersecretion and mucus retention.
The device promotes and improves bronchial drainage by enhancing mobilization of bronchial secretions via high frequency oscillatory vibrations and intermittent negative pressure to the airway during exhalation, the company explained.
Inogen intends to pursue a limited launch of SIMEOX 200 in targeted sites in 2025.
During the pre-market hours, Inogen's stock is trading at $8.90, up 3.73 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.